menu
    • menu

    Company profile for Axplora

    NEW Drugs in Dev: 5
    Axplora-PSE
    News
    Axplora consolidates global UDCA manufacturing at Vizag facility

    10 Jun 2026

    // PRESS RELEASE

    Axplora Invests $60 Million in HPAPI Expansion at Farmabios Site

    17 Mar 2026

    // PRESS RELEASE

    Axplora Expands Le Mans Lyophilization Operations, Appoints Head

    18 Feb 2026

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Axplora

    Contact Supplier

    Website

    CPhI Milan

    Booth #3C1

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.pharmacompass.com/video-pharmareel/axplora-farmabios-pharmazell-and-novasep/pioneering-innovative-api-manufacturing-solutions

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Axplora is your partner of choice for complex APIs.

    Related CompaniesRelated Companies

    About

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AxploraGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Headquarters, HochstraB-Süd 7, 83064 Raubling
    Telephone
    Telephone
    Client Email
    Email
    axplora@axplora.com
    Client Website
    Website
    https://www.axplora.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/axplora
    youtube
    YouTube
    http://www.youtube.com/@axplora5386
    Twitter
    Twitter
    Contact Info
    Others

    Instagram : https://www.instagram.com/axplora.group/

    Facebook : https://www.facebook.com/profile.php?id=100086944601878

    YouTube : https://www.youtube.com/channel/UCTuVYD8er8sbIdDE9QYksQA 

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Milan

    Booth #3C1

    envelop Contact Supplier

    CPhI Milan

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    "Axplora’s leading position in ADCs and how it is well-placed to serve the burgeoning GLP1 market"

    mic"Axplora’s leading position in ADCs and how it is well-placed to serve the burgeoning GLP1 market"

    This week, SpeakPharma interviews Martin Meeson, CEO of Axplora, a leading and reliable API manufacturing partner to some of the world’s biggest pharma and biotech companies. Meeson discusses Axplora’s expansion in the antibody-drug-conjugate (ADC) space and how it is well-placed to serve the exciting market for glucagon-like peptide 1 (GLP-1) drugs with its industrial footprint and purification technologies across several sites. 🔑 HIGHLIGHTS// API manufacturing partner to some of the world’s biggest pharma and biotech companies As a leader in the pharmaceutical industry, what inspired you to join Axplora? And, what do you consider the most rewarding aspect of your role as its CEO? When you look at Axplora as the custodian of strong brands like Farmabios, Pharmazell and Novasep you cannot help but be intrigued by what such breadth of offering and depth of technical expertise can achieve. Well, I was certainly intrigued! As a leader in the pharma space, the opportunity to guide an organization with several decades of experience is inspiring for me. For example, our site in Leverkusen was founded over 150 years ago by Alfred Nobel. With every meeting and site visit, I get increasingly impressed by the capabilities of the people that I meet. Now, it is my job to make sure that these capabilities are given the best opportunity to serve. In this sector, we have the privilege of working with our partners to supply and develop medicines that have such a positive impact on people’s lives. This for me is the most rewarding thing that we do. Sometimes the work that we do can seem a little far away from the patient. I always take time to remind myself, my staff, and hopefully also your readers of what we are doing and how our work impacts others. 🔑 HIGHLIGHTS// strong brands like Farmabios, Pharmazell and Novasep / positive impact on people’s lives How have recent industry developments influenced both API manufacturing and CDMO sectors, and what specific strategies has Axplora implemented to adapt to these changing market dynamics while maintaining its commitment to quality and innovation? As a CDMO, when you partner with us, there is always a focus on reliable supply, and we are still haunted by the challenges all of us faced during the pandemic. At Axplora, we have implemented numerous initiatives to increase the robustness of supply, particularly in looking at advances in sourcing and horizontal integration both within and across our network. At the same time, we have a strong focus on the impact that we are having on the planet and Axplora’s work in this area is tremendous — from increasing the amount and efficacy of waste management, notably the current programs around solvent recovery and recycling, to implementing more environment-friendly technologies such as electrochemistry. I am particularly excited by the cutting-edge work on moving to completely new processes that are water-based rather than solvent-based, creating a step change in impact for us and our partners. In addition, as a CDMO you have to constantly look at where your services fit within evolving markets. Axplora’s expansion in the ADC sector is an excellent example of tracking and investing in emerging technologies. Of note also is the current demand for GLP-1 medicines, and Axplora is well-placed to serve this exciting market with our industrial footprint in small molecules and purification technologies across several sites in our network. 🔑 HIGHLIGHTS// increase the robustness of supply / efficient waste management programs and environment-friendly technologies Can you discuss any recent advancement or breakthrough in API manufacturing or CDMO services at Axplora that have contributed to the company’s success? Our investment in ADC expansion is a key strength. Our Novasep business has some of the world’s leading capabilities in API manufacturing and purification. It is known worldwide for these capabilities. With increasing demand for GLP-1 drugs and the amazing impact they are having on patients globally, we are ready to support this growth across our extensive network. The race to oral dose medicines in this space is particularly exciting, and Axplora is looking forward to treating the vast patient population in diabetes and obesity. 🔑 HIGHLIGHTS// expansion in the ADC sector / treat the vast patient population in diabetes and obesity Looking ahead, what are some of the trends or developments you foresee in API manufacturing and CDMO services, and how is Axplora preparing to stay ahead of the curve in this ever-evolving pharmaceutical landscape? Whilst the landscape is evolving rapidly, regulations are not necessarily able to keep pace with the development of new molecules. The pandemic revealed that things can move more quickly. When I look at the challenging new regulation in adjacent spaces like cell therapy, I wonder how that pace can be applied to our sectors. To that end, you have to remain agile and responsive to customer needs. We have to ensure we invest to grow our capacity in the right areas. Our recent investments in Farmabios in Gropello Cairoli (Italy) to support our thriving steroids business and in Pharmazell in Vizag (India) to advance our specialty business are clear indications of how we can do this very successfully. It would be easier if I could point to just one thing that we are doing, but that is not how we win. The only way to stay ahead is by making a myriad of large and small adjustments and evolutions and that is where the Axplora group excels. Finally, one element I should mention is that we are part of a global supply chain. Therefore, our broad network stands ready to supply medicines to multiple geographies. Our investments reflect our worldwide customer base and ambitions. We are here to serve our partners and their patients. 🔑 HIGHLIGHTS// recent investments in Farmabios in Italy and Pharmazell in India / ready to supply medicines to multiple geographies

    Impressions: 3861

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/axplora-s-leading-position-in-adcs-and-how-it-is-well-placed-to-serve-the-burgeoning-glp1-market

    #SpeakPharma With Axplora
    23 May 2024
    Share info Share

    VLOG #PharmaReel

    read-more

    ReelPharmaPioneering Innovative API Manufacturing SolutionsPioneering Innovative API Manufacturing Solutions

    Pioneering Innovative API Manufacturing Solutions
    Pioneering Innovative API Manufacturing Solutions

    reelPioneering Innovative API Manufacturing Solutions

    Pioneer of world-class API manufacturing solutions with ADC, steroids and flow chemistry expertise, empowering 900+ customers.

    Impressions: 1955

    read-more

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-74273.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-18364.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CDMO Services for Pharmaceuticals 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-91740.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CDMO Services for ADCs 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-12663.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Finorga GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-9840.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Farmabios GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-65935.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    PharmaZell GMP Certificate 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-59580.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Novasep GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-71758.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Seripharm GMP Certificate 2021

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-25093.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Martin Meeson Appointed as CEO of Axplora

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-75596.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    PharmaZell & Novasep Announce the Closing of their Merger.

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmazell-gmbh-party-content-1649482221.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    In Negotiations with Novasep for Complex Small Molecules & ADCs

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmazell-gmbh-party-content-1631849200.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with  leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey.  NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region.  Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4394

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

    #PharmaFlow by PHARMACOMPASS
    16 Oct 2025
    Share Share
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 9994

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 6405

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5718

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Axplora consolidates global UDCA manufacturing at Vizag facility
    Axplora consolidates global UDCA manufacturing at Vizag facility

    10 Jun 2026

    // PRESS RELEASE

    https://www.axplora.com/axplora-consolidates-udca-manufacturing-at-vizag-site-to-strengthen-integrated-global-supply-and-support-future-growth/

    PRESS RELEASE
    10 Jun 2026
    Share Share
    Axplora Invests $60 Million in HPAPI Expansion at Farmabios Site
    Axplora Invests $60 Million in HPAPI Expansion at Farmabios Site

    17 Mar 2026

    // PRESS RELEASE

    https://www.axplora.com/biopharmas-growing-emphasis-on-highly-potent-drugs-drives-axplora-manufacturing-expansion/

    PRESS RELEASE
    17 Mar 2026
    Share Share
    Axplora Expands Le Mans Lyophilization Operations, Appoints Head
    Axplora Expands Le Mans Lyophilization Operations, Appoints Head

    18 Feb 2026

    // PRESS RELEASE

    https://www.axplora.com/axplora-announces-multi-million-euro-investment-to-expand-lyophilization-at-le-mans-and-appoints-francois-houbart-as-head-of-site/

    PRESS RELEASE
    18 Feb 2026
    Share Share
    Axplora initiates global investments exceeding €100m in 2025
    Axplora initiates global investments exceeding €100m in 2025

    08 Oct 2025

    // PRESS RELEASE

    https://www.axplora.com/axplora-initiates-global-investments-exceeding-e100m-in-2025/

    PRESS RELEASE
    08 Oct 2025
    Share Share
    Axplora Announces €6.5 Million Investment at Vizag Site
    Axplora Announces €6.5 Million Investment at Vizag Site

    05 Aug 2025

    // PRESS RELEASE

    https://www.axplora.com/axplora-announces-e6-5-million-investment-at-vizag-site-and-fda-inspection-success-across-indian-operations/

    PRESS RELEASE
    05 Aug 2025
    Share Share
    Axplora Doubles Farmabios Footprint with €35M Expansion
    Axplora Doubles Farmabios Footprint with €35M Expansion

    04 Jul 2025

    // PRESS RELEASE

    https://www.axplora.com/axplora-announces-further-40m-expansion-at-farmabios-to-double-footprint-and-fuel-long-term-growth/

    PRESS RELEASE
    04 Jul 2025
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Acetylcysteine

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-08-07

    Pay. Date : 2013-04-03

    DMF Number : 5836

    Submission : 1985-03-29

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R2-CEP 1995-028 - Rev 04

    Issue Date : 2020-12-15

    Type : Chemical

    Substance Number : 967

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10377

    Registrant's Address : ROSENHEIMER STR. 43, D-83064 RAUBLING, GERMARY

    Initial Date of Registration : 2007-12-19

    Latest Date of Registration :

    EU-WC NDC KDMF VMF EU, CA, ... arrow-down
    ✖
    Available Reg. Filing : EU, CA, BR, CN
    AUDIT arrow-down
    Axplora CB

    02

    Betamethasone Valerate

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2018-08-14

    Pay. Date : 2018-07-09

    DMF Number : 12749

    Submission : 1997-11-18

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2002-078 - Rev 03

    Issue Date : 2021-03-22

    Type : Chemical

    Substance Number : 811

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 304MF10098

    Registrant's Address : Via Pavia, 1-27027 Gropello Cairoli, Pavia, Italy

    Initial Date of Registration : 2022-07-06

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46439-8711

    Start Marketing Date : 1989-05-31

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT arrow-down
    Axplora CB

    03

    Medroxyprogesterone Acetate

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 12695

    Submission : 1997-10-15

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2002-191 - Rev 03

    Issue Date : 2023-07-03

    Type : Chemical

    Substance Number : 673

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 222MF10098

    Registrant's Address : Via Pavia, 1-27027 Gropello Cairoli, Pavia, Italy

    Initial Date of Registration : 2010-03-17

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46439-8749

    Start Marketing Date : 2015-09-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Saehan Pharmaceutical Co., Ltd.

    Registration Date : 2005-08-31

    Registration Number : 20050831-58-B-142-01

    Manufacturer Name : Farmabios SpA

    Manufacturer Address : Farmabios SpA via Pavia 1 27027 GROPELLO CAIROLI-Pavia ITALY

     VMF Others AUDIT arrow-down
    Axplora CB

    04

    Mesalazine

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-12-16

    Pay. Date : 2014-11-28

    DMF Number : 8070

    Submission : 1989-05-09

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2003-203 - Rev 03

    Issue Date : 2023-11-08

    Type : Chemical

    Substance Number : 1699

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10036

    Registrant's Address : ROSENHEIMER STR. 43 D-83064 RAUBLING, Germany

    Initial Date of Registration : 2007-02-13

    Latest Date of Registration :

    EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Takeda Pharmaceutical Korea

    Registration Date : 2021-10-05

    Registration Number : 20210521-209-J-766(1)

    Manufacturer Name : PharmaZell (India) Private Ltd

    Manufacturer Address : Plot No. 115, Visakha Pharmacity Limited, SEZ, Parawada, Anakapalli – 531019 Andhra Pradesh, India

     VMF EU, CA, ... arrow-down
    ✖
    Available Reg. Filing : EU, CA, TW, BR, TH
    AUDIT arrow-down
    Axplora CB

    05

    Triamcinolone Acetonide

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-05-21

    Pay. Date : 2013-05-14

    DMF Number : 14693

    Submission : 2000-02-01

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2000-075 - Rev 07

    Issue Date : 2021-02-25

    Type : Chemical

    Substance Number : 533

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 305MF10085

    Registrant's Address : Via Pavia, 1-27027 Gropello Cairoli, Pavia, Italy

    Initial Date of Registration : 2023-07-19

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46439-8782

    Start Marketing Date : 2025-02-20

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Sam-O Pharmaceutical Co., Ltd.

    Registration Date : 2015-01-30

    Registration Number : 20150130-65-B-382-10

    Manufacturer Name : Farmabios SpA

    Manufacturer Address : Via Pavia 1-27027 Gropello Cairoli(PV), Italy_x000D_

     VMF Others AUDIT arrow-down
    Axplora CB

    06

    Triamcinolone Acetonide

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-06-20

    Pay. Date : 2013-01-10

    DMF Number : 21591

    Submission : 2008-05-01

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2021-300 - Rev 01

    Issue Date : 2024-05-03

    Type : Chemical

    Substance Number : 533

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 223MF10049

    Registrant's Address : Via Pavia, 1-27027 Gropello Cairoli, Pavia, Italy

    Initial Date of Registration : 2011-04-12

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46439-8783

    Start Marketing Date : 2025-02-20

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT arrow-down
    Axplora CB

    07

    Beclomethasone Dipropionate

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-04-25

    Pay. Date : 2019-04-22

    DMF Number : 12813

    Submission : 1998-01-05

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2001-315 - Rev 02

    Issue Date : 2017-06-28

    Type : Chemical

    Substance Number : 654

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46439-8785

    Start Marketing Date : 2025-03-10

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Kolon Pharmaceutical Co., Ltd.

    Registration Date : 2013-06-10

    Registration Number : 20130610-186-I-285-01

    Manufacturer Name : Farmabios SpA

    Manufacturer Address : Gropello Cairoli (PV) - Via Pavia, 1, Italy.

     VMF CN, SA arrow-down
    ✖
    Available Reg. Filing : CN, SA
    AUDIT arrow-down
    Axplora CB

    08

    Fluocinolone Acetonide

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-05-16

    Pay. Date : 2013-05-07

    DMF Number : 17395

    Submission : 2004-05-19

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 218MF10445

    Registrant's Address : Via Pavia, 1-27027 Gropello Cairoli, Pavia, Italy

    Initial Date of Registration : 2006-04-27

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46439-8709

    Start Marketing Date : 1998-04-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF VMF CN, SAU arrow-down
    ✖
    Available Reg. Filing : CN, SAU
    AUDIT arrow-down
    Axplora CB

    09

    Megestrol Acetate

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2021-03-25

    Pay. Date : 2021-03-22

    DMF Number : 12662

    Submission : 1997-09-20

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2002-154 - Rev 05

    Issue Date : 2019-02-11

    Type : Chemical

    Substance Number : 1593

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46439-8722

    Start Marketing Date : 1998-07-22

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Sam-O Pharmaceutical Co., Ltd.

    Registration Date : 2021-04-09

    Registration Number : 20210409-211-J-738

    Manufacturer Name : Farmabios SpA@Micro-Macinazione SA@IMS srl@Micro-Macinazione SA

    Manufacturer Address : Via Pavia 1-27027 Gropello Cairoli (PV), Italy@Zona Artigianale 11, 6995 Madonna del Piano, Switzerland@Via Venezia Giulia 23, 20157 Milano@Via Cantonale 4, 6998 Monteggio, Switzerland

     VMF Others AUDIT arrow-down
    Axplora CB

    10

    Propafenone Hydrochloride

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-03-07

    Pay. Date : 2013-02-15

    DMF Number : 10641

    Submission : 1993-12-16

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2005-236 - Rev 03

    Issue Date : 2018-06-08

    Type : Chemical

    Substance Number : 2103

    Status : Valid

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Abbott Korea Ltd.

    Registration Date : 2022-01-24

    Registration Number : 20220124-209-J-1222

    Manufacturer Name : PharmaZell GmbH

    Manufacturer Address : Rosenheimer Straße 43 83064 Raubling Germany

     VMF EU, CA, ... arrow-down
    ✖
    Available Reg. Filing : EU, CA, BR, TH, ID
    AUDIT arrow-down
    Axplora CB
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    LISTED APIs

    read-more
    read-more
    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    16Alpha-Hydroxyprednisolone

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    01

    16Alpha-Hydroxyprednisolone

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    6-Methyluracil

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    02

    6-Methyluracil

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Acetylcysteine

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    03

    Acetylcysteine

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Amcinonide

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    04

    Amcinonide

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Balsalazide Disodium

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    05

    Balsalazide Disodium

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Beclomethasone Dipropionate

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    06

    Beclomethasone Dipropionate

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Betahistine Dihydrochloride

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    07

    Betahistine Dihydrochloride

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Betahistine Dimesilate

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    08

    Betahistine Dimesilate

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Betamethasone

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    09

    Betamethasone

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Betamethasone Dipropionate

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Levera...
    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    10

    Betamethasone Dipropionate

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs o...

    Axplora CB

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Axplora full-view
    Antibody-Drug Conjugate (ADC) Development
    full-view
    Complex Active pharmaceutical ingredients
    full-view
    Custom Manufacturing of Complex & Original Molecules
    full-view
    Containment of High Potency API (HPAPI)
    full-view
    Small Molecule API Development Services
    full-view
    Separation & Purification of APIs
    full-view
    Continuous Processes For Hazardous Reactions
    full-view
    Hazardous Chemistry services
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Axplora and get a quotation

    Axplora is a supplier offers 124 products (APIs, Excipients or Intermediates).

    Find Acetylcysteine bulk with DMF, CEP, JDMF offered by Axplora

    Find Betamethasone Valerate bulk with DMF, CEP, JDMF offered by Axplora

    Find Medroxyprogesterone Acetate bulk with DMF, CEP, JDMF offered by Axplora

    Find Mesalazine bulk with DMF, CEP, JDMF offered by Axplora

    Find Triamcinolone Acetonide bulk with DMF, CEP, JDMF offered by Axplora

    Find Beclomethasone Dipropionate bulk with DMF, CEP offered by Axplora

    Find Betamethasone Dipropionate bulk with DMF, CEP offered by Axplora

    Find Budesonide bulk with DMF, CEP offered by Axplora

    Find Clobetasol Propionate bulk with DMF, JDMF offered by Axplora

    Find Difluprednate bulk with DMF, JDMF offered by Axplora

    Find Fluocinolone Acetonide bulk with DMF, JDMF offered by Axplora

    Find Fluocinonide bulk with DMF, JDMF offered by Axplora

    Find Fluticasone Propionate bulk with DMF, CEP offered by Axplora

    Find Formoterol Fumarate bulk with DMF, CEP offered by Axplora

    Find Fulvestrant bulk with DMF, CEP offered by Axplora

    Find Megestrol Acetate bulk with DMF, CEP offered by Axplora

    Find Methylene Blue bulk with DMF, CEP offered by Axplora

    Find Methylprednisolone Acetate bulk with DMF, CEP offered by Axplora

    Find Mometasone Furoate bulk with DMF, CEP offered by Axplora

    Find Prednisolone Acetate bulk with DMF, CEP offered by Axplora

    Find Propafenone Hydrochloride bulk with DMF, CEP offered by Axplora

    Find Teriflunomide bulk with DMF, CEP offered by Axplora

    Find Triamcinolone Hexacetonide bulk with DMF, CEP offered by Axplora

    Find Amcinonide bulk with JDMF offered by Axplora

    Find Balsalazide Disodium bulk with DMF offered by Axplora

    Find Beclomethasone Dipropionate bulk with DMF offered by Axplora

    Find Busulfan bulk with DMF offered by Axplora

    Find Cannabidiol bulk with DMF offered by Axplora

    Find Carbocisteine bulk with JDMF offered by Axplora

    Find Celecoxib bulk with DMF offered by Axplora

    Find Chlormadinone Acetate bulk with JDMF offered by Axplora

    Find Cholic Acid bulk with CEP offered by Axplora

    Find Clocortolone Pivalate bulk with DMF offered by Axplora

    Find Cyproterone Acetate bulk with DMF offered by Axplora

    Find Cystine bulk with CEP offered by Axplora

    Find Desonide bulk with DMF offered by Axplora

    Find Desoximetasone bulk with DMF offered by Axplora

    Find Dexamethasone bulk with DMF offered by Axplora

    Find Diflorasone bulk with JDMF offered by Axplora

    Find Diflucortolone Valerate bulk with JDMF offered by Axplora

    Find Esmolol Hydrochloride bulk with DMF offered by Axplora

    Find Exemestane bulk with DMF offered by Axplora

    Find Fludrocortisone Acetate bulk with DMF offered by Axplora

    Find Flumethasone bulk with DMF offered by Axplora

    Find Flunisolide bulk with DMF offered by Axplora

    Find Fluorometholone bulk with DMF offered by Axplora

    Find Fluticasone Furoate bulk with DMF offered by Axplora

    Find Halcinonide bulk with DMF offered by Axplora

    Find Hydrocortisone bulk with DMF offered by Axplora

    Find Hydrocortisone Acetate bulk with CEP offered by Axplora

    Find Icosapent Ethyl bulk with DMF offered by Axplora

    Find Indapamide bulk with CEP offered by Axplora

    Find L-Cysteine Hydrochloride bulk with CEP offered by Axplora

    Find Loteprednol Etabonate bulk with DMF offered by Axplora

    Find Medroxyprogesterone Acetate bulk with DMF offered by Axplora

    Find Melphalan Hydrochloride bulk with DMF offered by Axplora

    Find Mesalazine bulk with JDMF offered by Axplora

    Find Methyl Testosterone bulk with DMF offered by Axplora

    Find Methylprednisolone Hemisuccinate bulk with CEP offered by Axplora

    Find Mometasone Furoate bulk with DMF offered by Axplora

    Find Prednicarbate bulk with CEP offered by Axplora

    Find Prednisolone Valerate Acetate bulk with JDMF offered by Axplora

    Find Tirofiban Hydrochloride Monohydrate bulk with DMF offered by Axplora

    Find Triamcinolone Acetonide bulk with CEP offered by Axplora

    Find Triamcinolone Diacetate bulk with DMF offered by Axplora

    Find Ursodeoxycholic Acid bulk with JDMF offered by Axplora

    Find 16Alpha-Hydroxyprednisolone bulk offered by Axplora

    Find 6-Methyluracil bulk offered by Axplora

    Find Amifostine bulk offered by Axplora

    Find Beclomethasone Dipropionate bulk offered by Axplora

    Find Betahistine Dihydrochloride bulk offered by Axplora

    Find Betahistine Dimesilate bulk offered by Axplora

    Find Betamethasone bulk offered by Axplora

    Find Brexanolone bulk offered by Axplora

    Find Budesonide bulk offered by Axplora

    Find Carbocysteine Lysine bulk offered by Axplora

    Find Celecoxib bulk offered by Axplora

    Find Chenodeoxycholic Acid bulk offered by Axplora

    Find Clobetasol Propionate bulk offered by Axplora

    Find Clobetasone Butyrate bulk offered by Axplora

    Find Cysteamine Bitartrate bulk offered by Axplora

    Find Delmadinone acetate bulk offered by Axplora

    Find Dexamethasone bulk offered by Axplora

    Find Dexamethasone Sodium Phosphate bulk offered by Axplora

    Find Difluprednate bulk offered by Axplora

    Find Encorafenib bulk offered by Axplora

    Find Eravacycline bulk offered by Axplora

    Find Etoricoxib bulk offered by Axplora

    Find Flumethasone Pivalate bulk offered by Axplora

    Find Fluocinonide bulk offered by Axplora

    Find Fluocortolone Caproate bulk offered by Axplora

    Find Fluocortolone Pivalate bulk offered by Axplora

    Find Fluprednidene Acetate bulk offered by Axplora

    Find Flurandrenolone bulk offered by Axplora

    Find Halometasone bulk offered by Axplora

    Find Lysine bulk offered by Axplora

    Find Lysine Acetate bulk offered by Axplora

    Find Lysine Hydrochloride bulk offered by Axplora

    Find Magnesium Orotate bulk offered by Axplora

    Find Mesalazine bulk offered by Axplora

    Find Methylprednisolone bulk offered by Axplora

    Find Methylprednisolone Aceponate bulk offered by Axplora

    Find Mivacurium Chloride bulk offered by Axplora

    Find Nitroglycerin bulk offered by Axplora

    Find Olaparib bulk offered by Axplora

    Find Omadacycline bulk offered by Axplora

    Find Omega-3-Acid Ethyl Esters 90 bulk offered by Axplora

    Find Osaterone acetate bulk offered by Axplora

    Find Paramethasone Acetate bulk offered by Axplora

    Find Prednisolone bulk offered by Axplora

    Find Prednisolone Acetate bulk offered by Axplora

    Find Prednisolone Sodium Metasulfobenzoate bulk offered by Axplora

    Find Revefenacin bulk offered by Axplora

    Find Ruxolitinib Phosphate bulk offered by Axplora

    Find Salmeterol Xinafoate bulk offered by Axplora

    Find Selinexor bulk offered by Axplora

    Find Tauroursodeoxycholic Acid bulk offered by Axplora

    Find Testosterone Cypionate bulk offered by Axplora

    Find Tirofiban bulk offered by Axplora

    Find Triamcinolone bulk offered by Axplora

    Find Triamcinolone Acetonide bulk offered by Axplora

    Find Vamorolone bulk offered by Axplora

    Find Zavegepant HCl bulk offered by Axplora

    Find Zinc Orotate bulk offered by Axplora

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search